Reducing Stigma While Optimizing Care of the Dually Diagnosed Patient

Sign in (or create a FREE account) to register or access your existing registration.

Course Description

Gain tools to reduce the use of stigmatizing terms and learn how to incorporate patient first language when working with those with a substance use disorder (SUD). During this session, you will take a deeper dive into how bias towards the SUD population, race, and gender, all impact access to SUD services and care provided for mental illness. In addition, you will gain tools to take back to your practice site to enhance the care of patients living with co-occurring disorders.

Learning Objectives

  1. Illustrate how bias towards substance use disorders (SUDs) impacts treatment of mental illness.
  2. Outline non-stigmatizing terms when referring to SUDs and co-occurring psychiatric disorders.
  3. Employ strategies to identify and reduce stigma in your current practice setting.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Faculty

Michelle Geier, PharmD, BCPP, APh
View biographical information

Michelle Geier, PharmD, BCPP, APh
Psychiatric Clinical Pharmacist Supervisor
San Francisco Department of Public Health
San Francisco, CA

Dr. Michelle Geier grew up in Sitka, Alaska and moved to Seattle, Washington to attend the University of Washington for undergraduate studies and obtain a PharmD from the School of Pharmacy. She completed a PGY1 at the VA Puget Sound and a PGY2 in Psychiatry at the University of California San Francisco/San Francisco Department of Public Health. After completing her residency, she accepted a position as a Psychiatric and Substance Use Disorders Clinical Pharmacist position with the San Francisco Department of Public Health. In 2016, she was promoted to Psychiatric Clinical Pharmacist Supervisor. 
 
Dr. Geier provides ambulatory care psychiatric services in a public health specialty mental health clinic. Under s collaborative practice agreement, she prescribes mental health and substance use disorder medications. Her clients are primarily dual-diagnosis and many are experiencing homelessness. She also supervises 6 psychiatric clinical pharmacists and serves as the residency program director for the Zuckerberg San Francisco General Hospital PGY2 in psychiatry. Her area of specialty is substance use disorders. This includes developing pharmacy clinical practices at a pharmacy that serves 200 clients taking buprenorphine and providing consultations for providers throughout the Department of Public Health. She participates in interdisplinary case conferences with the inpatient addiction medicine service, outpatient bridge clinic and street medicine team. Some of the projects she has worked on include naloxone prescribing by pharmacists, deprescribing sedative-hypnotics and initiating buprenorphine in high risk areas with transitions to outpatient (including jail, inpatient and the emergency department). 
 
Dr. Geier has been a member of CPNP for 10 years. She has been a member of the Resident and New Practitioner Committee, Community Leaders Council, Recertification Editorial Board and Substance Use Disorders Steering Committee. Most recently, she has participated in the Strategic Planning Committee and is excited to see where CPNP is going in the future.

Course Requirements

To receive ACPE credit for this session, you must:

  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the evaluation at the end of the activity.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Continuing Education Credit and Disclosures

Activity Date: 11/03/2021
ACPE Contact Hours: 1
ACPE Number: 0284-0000-21-051-H04-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

View disclaimer and disclosure of off-label use

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

View fair balance and integrity statement

It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.